Micro-x Ltd. · ASX:MX1
Micro-x — Investor Presentation (July 2021)
19 slides from Micro-x's investor presentation, Jul 29, 2021
Slide 1: Micro-X Company Presentation announcement
Micro-X Limited, ABN 21 153 273 735 MICRO-X COMPANY PRESENTATION For personal use only Adelaide, Australia, 29 July 2021: Australian hi-tech company Micro-X Ltd (ASX:MX1) (Micro-X or the Company), a leader in cold cathode x-ray technology for the healthcare and security markets globally, is pleased
Slide 2: Company Update: A new era in X-ray imaging
For personal use only ACN 153 273 735 ASX: MX1 Company Update 29 July 2021 Peter Rowland Managing Director & CEO A new era in X-ray imaging
Slide 3: Important Notice Disclaimer
I M P O R TA N T N O T I C E DISCLAIMER SCOPE & LIMITATIONS This Presentation has been prepared by Micro-X Limited (Micro-X or the Company) (ASX.MX1). The Presentation is a summary only and does not For personal use only contain all the information about the Company’s assets and liabilities, financi
Slide 4: Miniaturising X-ray: First Mover in Next Generation X-ray
M I N I AT U R I S I N G X - R AY First Mover in Next Generation X-ray for Global Health and Security Markets For personal use only Platform technology in cold cathode x-ray • X-ray products with significant reduction in size, weight and power • Patented technology – platform for health and new secu
Slide 5: Our Strategy: To Monetise Our First Mover Advantage
O U R S T R AT E G Y To Monetise Our ‘First Mover’ Advantage Successful first movers in breakthrough For personal use only technology move quickly: Early Commercial success becomes a barrier to commercial domination entry for others OUR GOAL Four production lines: - common technology platforms Creat
Slide 6: Mobile Digital Radiology: Extending Bedside Imaging
M O B I L E D I G I TA L R A D I O L O G Y Extending Bedside Imaging with Light weight and Ultra-mobility For personal use only THE PRODUCT RANGE OEM Products – Carestream DRX Revolution Nano • First sold 2018 – now operating in 20+ countries • Other, non-exclusive OEM partnerships in development Mi
Slide 7: Mobile DR – Rover Medical: Building Commercial Capability
MOBILE DR – ROVER MEDICAL Building Commercial Capability – New Markets and Sales Channels U.K, 6% For personal use only Americas, Rover Medical – launched in mid 2021 with multiple EU, 17% $3.6m 28% distributors and dealerships Focus now on building installed base Oceania, Sales in FY21 20% Building
Slide 8: Mobile DR: Rover for Military & Remote Users
M O B I L E D R : R O V E R F O R M I L I TA RY & R E M O T E U S E R S First contract for ADF – Strong Military Interest for deployed medical facilities For personal use only Rover Military for use in combat support, disaster relief & humanitarian aid - addressing unmet need $1.4m Sales via WHO in
Slide 9: Mobile DR – Rover Veterinary
M O B I L E D R - R O V E R V E T E R I N A RY New Radiology Market – Same benefits for mobility For personal use only Rover Vet launched in 2021 for small animal veterinary market 3,000 Australian Vet Smaller size and mobility improves workflows & productivity Practices use diagnostic radiology Vet
Slide 10: IED X-ray Camera
I E D X - R AY C A M E R A Next Generation Security Device to Save Lives For personal use only $1.8b X-Ray camera takes images like a camera - one sided viewing without separate detector Addressable market Bomb disposal technicians face life threatening situation when ‘over the target’ placing a con
Slide 11: Airport Self-Service Checkpoint
A I R P O R T S E L F - S E RV I C E C H E C K P O I N T US Dept. of Homeland Security – Two Contracts Totalling US$4m For personal use only • A blend of backscatter and transmission X-ray to provide three dimensional imaging of carry on luggage US$24.0b • Integrated body scanner and passport reader
Slide 12: Brain CT Imaging for Stroke Diagnosis
BRAIN CT IMAGING FOR STROKE DIAGNOSIS Pre-Hospital Diagnosis & Treatment in Ambulance - $8m MRFF Funding Awarded For personal use only • CT imaging with no moving parts – small enough and affordable to be fitted to every ambulance US$5.0b Addressable market • Early stroke diagnosis allows treatment
Slide 13: Sequenced Product Rollout Across Four Production Lines
SVI EGRNV IIEFWI CO A O F N M IT C RM O -A X RKETS ACROSS FOUR PRODUCTION LINES Next generation Sequenced X-ray Product Rollout forManufacturing as CNT global healthExpandsand security markets For personal use only MOBILE DR RANGE IED X-RAY CAMERA AIRPORT CHECKPOINT BRAIN CT SCANNER 2018 2022* 2023*
Slide 14: June 2021 Quarter Highlights
JUNE 2021 QUARTER HIGHLIGHTS Advancing & Investing in our Commercial Capabilities For personal use only 1 Expanding commercial range – New Mobile DR products • Rover Medical receives FDA clearance – launched in US healthcare market • Rover Veterinary launched – first sale and Australian distributor
Slide 15: Established Capabilities
E S TA B L I S H E D C A PA B I L I T I E S Key Disciplines – Engineering Design, Development and Manufacturing For personal use only Above: manufacturing in Tonsley facility
Slide 16: Experienced Leadership
EXPERIENCED LEADERSHIP Technical and Commercial Expertise – To Support Objectives For personal use only Peter Rowland David Knox Patrick O’Brien Yasmin King Dr Alexander Gosling, AM Jim McDowell Managing Director & CEO Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executiv
Slide 17: Corporate Snapshot
C O R P O R AT E S N A P S H O T Growth Stage Company with Institutional Support For personal use only MX1 - Share Trading ( 27 July 2020 to 27 July 2021) Millions $0.45 12.0 $0.40 10.0 $0.35 $0.30 8.0 $0.25 6.0 $0.20 $0.15 4.0 $0.10 2.0 $0.05 $0.00 0.0 27 03 10 17 24 31 07 14 21 28 05 12 19 26 02 0
Slide 18: Overview of Micro-X: Milestones and Achievements
OVERVIEW OF MICRO-X M I Lgeneration Next E S TO N E SX-ray & Afor C Hglobal IEVEM E N T and health S security markets Initiatives to Deliver Commercial Outcomes for all Stakeholders For personal use only First IED X-ray Camera Demonstration Increasing Mobile DR Sales Growing Micro-X Rover paths to m
Slide 19: Thank You
For personal use only ACN 153 273 735 ASX: MX1 Thank You Peter Rowland Managing Director & CEO A new era in X-ray imaging